Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed mild COVID-19 (NEWS scoring system 0-4)~Exclusion Criteria:~* unable to take oral medication~* pregnancy or breast feeding~* immunocompromised patients~* creatinine clearance (CCL) \< 30 mL/min~* aspartate transaminase (AST) or alanine transaminase (ALT) \> 5 times Upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Lopinavir/ritonavir (Type: EXPERIMENTAL): Lopinavir/ritonavir 200mg/100mg 2 tablets by mouth, every 12 hours for 7-10 days
- Hydroxychloroquine (Type: ACTIVE_COMPARATOR): Hydroxychloroquine 400mg by mouth, every 24 hours for 7-10 days
- Control (Type: NO_INTERVENTION): No lopinavir/ritonavir and hydroxychloroquine

Based on this trial design, predict the completion outcome and termination type (if applicable).